Cerebrolysin

What It Is

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue via standardized enzymatic proteolysis. It has been approved in over 40 countries for stroke recovery, traumatic brain injury (TBI), and dementia — but remains unapproved by the FDA in the United States. Multiple randomized controlled trials have evaluated its neuroprotective potential: in vascular dementia, a 24-week RCT found ADAS-cog+ improvements of 10.6 points vs 4.4 for placebo. A meta-analysis of mild-to-moderate Alzheimer's disease trials concluded a favorable benefit-risk ratio, though Cochrane reviewers have called for larger, more rigorous studies. In post-TBI recovery, a 2025 review in a pharmacology journal synthesized preclinical and clinical evidence supporting Cerebrolysin's neurotrophic factor-like activity, including BDNF and GDNF modulation, synaptogenesis promotion, and anti-apoptotic effects. Adverse reactions are generally mild and transient (vertigo, agitation, feeling hot). As of 2026, no new pivotal trials have been announced, but Cerebrolysin continues to be used clinically in Europe, Asia, and Latin America as an adjunctive neuroprotective therapy.

Why Researchers Study It

Cerebrolysin is one of the few clinically available neuropeptide preparations with decades of use across multiple countries. Its multi-target neurotrophic mechanism — affecting BDNF, synaptogenesis, and anti-apoptosis simultaneously — makes it a unique research subject for understanding peptide-based neuroprotection in stroke, TBI, and neurodegenerative disease.

Proposed Mechanisms

• Mimics neurotrophic factors (BDNF, GDNF, CNTF) to support neuronal survival
• Promotes synaptogenesis and dendritic branching in damaged brain regions
• Exhibits anti-apoptotic properties in ischemic and traumatic brain injury models
• Modulates neuroinflammatory cascades following acute brain injury
• Enhances cholinergic transmission relevant to cognitive function

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Cerebrolysin compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Bornstein NM. et al. — Cerebrolysin in acute ischemic stroke. J Neurol Sci. 2018 PubMed
2. [2] Guekht AB. et al. — Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. 2010 PubMed
3. [3] Cerebrolysin in post-TBI recovery: Pharmacology and clinical evidence — ScienceDirect 2025 PubMed
4. [4] Alvarez XA. et al. — Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. 2015 PubMed

Related Peptides